Dubai: On World Patient Safety Day, the Dubai branch of NYSE-listed Becton, Dickinson and Company (BD) has reaffirmed its commitment to advancing patient safety.
Observed on September 17, BD said it is uniting with the global healthcare community in championing patient safety, emphasizing the role of healthcare professionals and medical technology companies, in addition to patients and their families, in ensuring unwavering patient care and safety.
"Patient safety is a core value that knows no boundaries, especially in the MENAT region," said Maher Elhassan, Vice President and General Manager of BD MENAT. "Our goal is to raise safety standards, decrease the risks associated with medical errors, and bolster the ongoing resilience of healthcare," he added.
Early last month, BD announced the enrollment of the first patient in the investigational device exemption (IDE) study, "Arch."
The study is a global, prospective, multi-centre, single-arm clinical study for treating complications from portal hypertension, assessing the safety and effectiveness of the investigational BD Liverty TIPS Stent Graft.
The ARCH Study will include 175 patients at up to 40 clinical study sites across the United States and Europe.
